Novartis
From Kidney Cancer Resource
Contents |
Overview
Ciba Geigy & Sandoz ammalgamated to form Novartis AG in 1996
To view their web site Click Here
Novartis UK, the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world.
This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs over 99,000 people worldwide and has a presence in over 140 countries.
Details
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs:
Innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group.
Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please Click Here.
The Novartis business is divided into four divisions:
Pharmaceuticals
Vaccines and Diagnostics
Sandoz (generics)
Consumer Health
Everolimus known also as Certican or RAD-001 is produced by Novartis.
A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called immunosuppressive agents and antiangiogenesis agents.
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties.
In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase.
Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production
Proleukin also called Aldesleukin is a Novartis product
PROLEUKIN® (aldesleukin) for injection therapy received FDA approval for treatment of metastatic renal cell carcinoma (metastatic kidney cancer) in 1992 and for treatment of metastatic melanoma (a type of skin cancer) in 1998.
Novartis is renowned for its commitment to:
- Innovative medicines – introducing new treatments annually
- Continued prime position in cardiology and oncology – blockbuster products
- Excellence in new product pipeline via research and development – one of the strongest in the industry with 75 products in the current pipeline
- Corporate responsibility in the UK and worldwide – contributing $755 million in aid and access to medicines in 2006
- Diversity and inclusion in employment
Contact Data UK
For UK Contact Data: Click Here
Media Releases
Novartis (KC) 19-May-08
- RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer
Articles
Huliq (KC) 27-May-08
- Novartis' Drug Everolimus fends off kidney cancer progression....
Reuters (KC) 17-May-08
- Experimental Novartis drug slows kidney cancer
PharmaTimes (KC) 13-Apr-08
Reuters (KC) 28-Feb-08
- Novartis kidney cancer drug clears key hurdle
Interactive Investor (KC) 28-Feb-08
- Novartis to seek cancer drug Everolimus clearance worldwide
MedPage (KC) 28-Feb-08
- Clear Benefit from Everolimus Brings Kidney Cancer Trial to a Halt
Reuters (KC) 28-Feb-08
- Novartis kidney cancer drug clears key hurdle
Novartis Press Release 28-Feb-08
- Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy
PharmaTimes (KC) 28-Feb-08
- Novartis' Everolimus shines in Phase III kidney cancer trial
Reuters (KC) 05-Dec-07
- Novartis to sell 4 new cancer drugs by 2011
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
